AOD-9604
Overview AOD‑9604 is a 16‑amino‑acid fragment derived from the C‑terminus of growth hormone (residues 177–191 with an added N‑terminal tyrosine). It was developed to study lipid‑metabolism pathways attributed to this region while minimizing classical growth‑hormone effects. Published work spans in‑vitro systems, animal models, and early clinical exploration focused on fat metabolism and energy balance. Mechanism of Action (Research Context) Evidence from preclinical and early clinical literature indicates modulation of lipid handling via β‑adrenergic pathways, with signals consistent with increased lipolysis and reduced lipogenesis. Summaries report little to no change in IGF‑1, suggesting activity distinct from the canonical GH/IGF‑1 axis. Findings vary by model, dose, and study design. Reported Findings in the Literature The following points consolidate outcomes commonly described across studies and reviews. Exact magnitude and reproducibility depend on protocol, population, and duration: • Stimulates fat breakdown (lipolysis): activation of pathways associated with mobilizing stored fatty acids for energy. • Inhibits fat creation (anti‑lipogenic signals): down‑regulation of processes linked to new fat cell formation and triglyceride storage. • Increases metabolic activity: observations consistent with higher energy expenditure in several models. • Targets adipose depots: reports describe preferential effects on stubborn or abdominal fat in some trials. • Muscle preservation signals: weight‑management studies emphasize fat‑focused effects with limited impact on lean mass. • Glycemic/IGF‑1 profile: summaries frequently note minimal effect versus full‑length GH in short‑term observations. Key Research‑Context Takeaways • Weight‑management research focus centered on fat reduction rather than increases in lean tissue. • Signals consistent with metabolic‑rate support observed in multiple models. • Short‑term tolerability generally favorable; efficacy outcomes mixed across longer studies. Chemical / Physical Information • Sequence: Tyr‑Leu‑Arg‑Ile‑Val‑Gln‑Cys‑Arg‑Ser‑Val‑Glu‑Gly‑Ser‑Cys‑Gly‑Phe (16 aa) • Approx. molecular weight: 1815 Da • Handling (general peptide guidance): store lyophilized material at −20 °C, protected from moisture/light; aliquot reconstituted solutions and avoid repeated freeze–thaw. Notes on Formats Studied Across the literature, AOD‑9604 has been evaluated in various experimental formats, including subcutaneous administration and oral formulations. Formulation, dosing, and endpoints differ by study and should be interpreted within each protocol’s design. Regulatory & Compliance Notes Referenced by anti‑doping organizations and not approved as an obesity therapy by major health authorities. Acquisition and use must follow applicable laws and institutional policies. Verify status before any regulated activity. References (Selection) • Endocrinology (2001): lipid metabolism and β‑adrenergic context. • Journal of Endocrinology & Metabolism (2013–2014): safety/tolerability summaries and IGF‑1 observations. • Obesity pharmacotherapy reviews (2013–2015): efficacy overview across trials. • Compound databases (e.g., PubChem) for identifiers and mass. • Anti‑doping organization statements/lists for status in sport. Disclaimer This is only intended for research purposes only. None of this is intended for consumption. This is only for educational purposes. ——————————– Selected References PMID: 18469936 — AOD9604 mechanisms in fat metabolism and lipolysis PMID: 20826578 — Growthhormone–related peptides and metabolic regulation PMID: 21753056 — Peptide modulation of visceral adiposity and body composition PMID: 25826926 — Endocrine and metabolic outcomes of GHaxis analogs Frontiers in Endocrinology — Peptidebased metabolic therapeutics Journal of Clinical Endocrinology & Metabolism — GHderivative peptides and metabolic effects FAQ : What is AOD9604? AOD9604 is a modified fragment of human growth hormone (hGH 176191) studied for its potential effects on lipid metabolism and fatoxidation pathways in research settings. How does AOD9604 work in research models? A2: AOD9604 interacts with metabolic signaling related to fat breakdown and energy use without activating full GH receptor pathways, making it unique for studying selective metabolic effects. Is AOD9604 approved for human or medical use? No. AOD9604 discussed here is a research compound and is not approved for therapeutic or general consumer use. What are researchers studying AOD9604 for? Research evaluates AOD9604 in contexts involving fat metabolism, adipocyte signaling, and energy balance in controlled experimental models. How is AOD9604 different from full growth hormone? AOD9604 is a short peptide fragment that does not stimulate IGF1 production or systemic GH activity, allowing researchers to isolate GHindependent metabolic pathways. How is AOD9604 evaluated in studies? AOD9604 is examined using in vitro metabolic assays and animal models th
For research use only. Not for human consumption.